{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T16:23:46Z","timestamp":1751473426694},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>One of the major concerns of patients with upper tract urothelial carcinoma (UTUC) treated with nephroureterectomy is intravesical recurrence (IVR). The purpose of the present study was to investigate the predictive risk factors for IVR after retroperitoneoscopic nephroureterectomy (RNU) for UTUC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinicopathological and surgical information were collected from the medical records of 73 patients treated with RNU for non-metastatic UTUC, without a history of or concomitant bladder cancer. The association between IVR after RNU and clinicopathological and surgery-related factors, including preoperative urine cytology and pneumoretroperitoneum time, was analyzed using the\u00a0Fisher exact test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the median follow-up time of 39.1\u00a0months, 18 (24.7%) patients had subsequent IVR after RNU. The 1- and 3-year IVR-free survival rates were 85.9% and 76.5%, respectively. The Fisher exact test revealed that prolonged pneumoretroperitoneum time of \u2265\u2009210\u00a0min was a risk factor for IVR in 1\u00a0year after RNU (<jats:italic>p<\/jats:italic>\u2009=\u20090.0358) and positive urine cytology was a risk factor for IVR in 3\u00a0years after RNU (<jats:italic>p<\/jats:italic>\u2009=\u20090.0352).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In UTUC, the occurrences of IVR in 1 and 3\u00a0years after RNU are highly probable when the pneumoretroperitoneum time is prolonged (\u2265\u2009210\u00a0min) and in patients with positive urine cytology, respectively. Strict follow-up after RNU is\u00a0more probable recommended for these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-021-00932-2","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T09:02:38Z","timestamp":1638435758000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Risk factor analysis of intravesical recurrence after retroperitoneoscopic nephroureterectomy for upper tract urothelial carcinoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Masato","family":"Yanagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Hamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Akatsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"932_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","volume":"79","author":"M Roupr\u00eat","year":"2021","unstructured":"Roupr\u00eat M, Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol. 2021;79:62\u201379.","journal-title":"Eur Urol"},{"issue":"48","key":"932_CR2","first-page":"e19","volume":"32","author":"N Tanaka","year":"2014","unstructured":"Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Kobayashi H, et al. The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol. 2014;32(48):e19-26.","journal-title":"Urol Oncol"},{"key":"932_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000338644","volume":"89","author":"D Hirano","year":"2012","unstructured":"Hirano D, Okada Y, Nagane Y, Satoh K, Mochida J, Yamanaka Y, et al. Intravesical recurrence after surgical management of urothelial carcinoma of the upper urinary tract. Urol Int. 2012;89:71\u20137.","journal-title":"Urol Int"},{"key":"932_CR4","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1186\/s12885-020-07623-5","volume":"20","author":"W Liu","year":"2020","unstructured":"Liu W, Wang Z, Liu S, Yao Y, Liu Y, Zhang G. Preoperative positive voided urine cytology predicts poor clinical outcomes in patients with upper tract urothelial carcinoma undergoing nephroureterectomy. BMC Cancer. 2020;20:1113.","journal-title":"BMC Cancer"},{"key":"932_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001834","author":"V Sharma","year":"2021","unstructured":"Sharma V, Miest TS, Juvet TS, Toussi A, Packiam V, Chamie K, et al. The impact of upper tract urothelial carcinoma diagnostic modality on intravesical recurrence after radical nephroureterectomy: a single institution series and updated meta-analysis. J Urol. 2021. https:\/\/doi.org\/10.1097\/JU.0000000000001834.","journal-title":"J Urol"},{"key":"932_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00345-012-0957-3","volume":"31","author":"E Xylinas","year":"2013","unstructured":"Xylinas E, Colin P, Audenet F, Phe V, Cormier L, Cussenot O, et al. Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. World J Urol. 2013;31:61\u20138.","journal-title":"World J Urol"},{"key":"932_CR7","doi-asserted-by":"crossref","unstructured":"Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, et al. Upper Tract Urothelial Carcinoma Collaboration. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2014;65:210\u20137.","DOI":"10.1016\/j.eururo.2012.04.052"},{"key":"932_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.suronc.2017.01.003","volume":"26","author":"K Shigeta","year":"2017","unstructured":"Shigeta K, Kikuchi E, Hagiwara M, Ando T, Mizuno R, Miyajima A, et al. Prolonged pneumoperitoneum time is an independent risk factor for intravesical recurrence after laparoscopic radical nephroureterectomy in upper tract urothelial carcinoma. Surg Oncol. 2017;26:73\u20139.","journal-title":"Surg Oncol"},{"key":"932_CR9","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1245\/s10434-019-07623-1","volume":"26","author":"K Shigeta","year":"2019","unstructured":"Shigeta K, Kikuchi E, Abe T, Hagiwara M, Ogihara K, Anno T, et al. Long-term oncologic outcomes of laparoscopic versus open radical nephroureterectomy for patients with T3N0M0 upper tract urothelial carcinoma: a multicenter cohort study with adjustment by propensity score matching. Ann Surg Oncol. 2019;26:3774\u201381.","journal-title":"Ann Surg Oncol"},{"key":"932_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.4143\/crt.2018.465","volume":"51","author":"SH Kim","year":"2019","unstructured":"Kim SH, Song MK, Kim JK, Hong B, Kang SH, Ku JH, et al. Laparoscopy versus open nephroureterectomy in prognostic outcome of patients with advanced upper tract urothelial cancer: a retrospective, multicentre, propensity-score matching analysis. Cancer Res Treat. 2019;51:963\u201372.","journal-title":"Cancer Res Treat"},{"key":"932_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12957-021-02236-z","volume":"19","author":"R Piszczek","year":"2021","unstructured":"Piszczek R, Nowak \u0141, Krajewski W, Chorbi\u0144ska J, Poletajew S, Moschini M, et al. Oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: an updated meta-analysis. World J Surg Oncol. 2021;19:129.","journal-title":"World J Surg Oncol"},{"key":"932_CR12","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.eururo.2012.02.019","volume":"61","author":"S Ni","year":"2012","unstructured":"Ni S, Tao W, Chen Q, Liu L, Jiang H, Hu H, et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. Eur Urol. 2012;61:1142\u201353.","journal-title":"Eur Urol"},{"key":"932_CR13","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.eururo.2014.11.035","volume":"67","author":"T Seisen","year":"2015","unstructured":"Seisen T, Granger B, Colin P, L\u00e9on P, Utard G, Renard-Penna R, et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol. 2015;67:1122\u201333.","journal-title":"Eur Urol"},{"key":"932_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"V Soukup","year":"2017","unstructured":"Soukup V, \u010capoun O, Cohen D, Hern\u00e1ndez V, Babjuk M, Burger M, et al. Prognostic performance and reproducibility of the 1973 and 2004\/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: a European Association of Urology non-muscle invasive bladder cancer guidelines panel systematic review. Eur Urol. 2017;72:801\u201313.","journal-title":"Eur Urol"},{"key":"932_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1272\/jnms.JNMS.2021_88-302","volume":"88","author":"M Yanagi","year":"2021","unstructured":"Yanagi M, Kimura G, Sekine T, Takeda H, Akatsuka J, Endo Y, et al. Factors associated with prolonged retroperitoneal laparoscopic radical nephrectomy performed by non-expert surgeons. J Nippon Med Sch. 2021;88:109\u201312.","journal-title":"J Nippon Med Sch"},{"key":"932_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/iju.14014","volume":"26","author":"S Yamamoto","year":"2019","unstructured":"Yamamoto S, Sakamoto S, Imamura Y, Sazuka T, Nakamura K, Inoue T, et al. Intravesical irrigation might prevent bladder recurrence in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. Int J Urol. 2019;26:791\u20136.","journal-title":"Int J Urol"},{"key":"932_CR17","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00345-013-1160-x","volume":"32","author":"L Zou","year":"2014","unstructured":"Zou L, Zhang L, Zhang H, Jiang H, Ding Q. Comparison of post-operative intravesical recurrence and oncological outcomes after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma. World J Urol. 2014;32:565\u201370.","journal-title":"World J Urol"},{"key":"932_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijc.10544","volume":"101","author":"C Hafner","year":"2002","unstructured":"Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer. 2002;101:1\u20136.","journal-title":"Int J Cancer"},{"key":"932_CR19","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1038\/sj.onc.1204671","volume":"20","author":"C Hafner","year":"2001","unstructured":"Hafner C, Knuechel R, Zanardo L, Dietmaier W, Blaszyk H, Cheville J, et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene. 2001;20:4910\u20135.","journal-title":"Oncogene"},{"key":"932_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1097\/01.ju.0000129541.23460.48","volume":"172","author":"H Miyake","year":"2004","unstructured":"Miyake H, Hara I, Kamidono S, Eto H. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. J Urol. 2004;172:1127\u20139.","journal-title":"J Urol"},{"key":"932_CR21","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.urology.2007.12.021","volume":"71","author":"M Babjuk","year":"2008","unstructured":"Babjuk M, Soukup V, Pesl M, Kost\u00edrov\u00e1 M, Drncov\u00e1 E, Smolov\u00e1 H, et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology. 2008;71:718\u201322.","journal-title":"Urology"},{"key":"932_CR22","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S0090-4295(01)01307-3","volume":"58","author":"IK Walsh","year":"2001","unstructured":"Walsh IK, Keane PF, Ishak LM, Flessland KA. The BTA stat test: a tumor marker for the detection of upper tract transitional cell carcinoma. Urology. 2001;58:532\u20135.","journal-title":"Urology"},{"key":"932_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/jjco\/hyi244","volume":"36","author":"A Kumar","year":"2006","unstructured":"Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol. 2006;36:172\u20135.","journal-title":"Jpn J Clin Oncol"},{"key":"932_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000330246","volume":"87","author":"M Jovanovic","year":"2011","unstructured":"Jovanovic M, Soldatovic I, Janjic A, Vuksanovic A, Dzamic Z, Acimovic M, et al. Diagnostic value of the nuclear matrix protein 22 test and urine cytology in upper tract urothelial tumors. Urol Int. 2011;87:134\u20137.","journal-title":"Urol Int"},{"key":"932_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0022-5347(17)43040-0","volume":"138","author":"WA See","year":"1987","unstructured":"See WA, Chapman PH. Heparin prevention of tumor cell adherence and implantation on injured urothelial surfaces. J Urol. 1987;138:182\u20136.","journal-title":"J Urol"},{"key":"932_CR26","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/jjco\/hyt129","volume":"43","author":"A Ito","year":"2013","unstructured":"Ito A, Shintaku I, Satoh M, Ioritani N, Tochigi T, Numata I, et al. Intravesical seeding of upper urinary tract urothelial carcinoma cells during nephroureterectomy: an exploratory analysis from the THPMG trial. Jpn J Clin Oncol. 2013;43:1139\u201344.","journal-title":"Jpn J Clin Oncol"},{"key":"932_CR27","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1200\/JCO.2012.45.2128","volume":"31","author":"A Ito","year":"2013","unstructured":"Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol. 2013;31:1422\u20137.","journal-title":"J Clin Oncol"},{"key":"932_CR28","doi-asserted-by":"crossref","unstructured":"O'Brien T, Ray E, Singh R, Coker B, Beard R; British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol. 2011;60:703\u201310.","DOI":"10.1016\/j.eururo.2011.05.064"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-021-00932-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-021-00932-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-021-00932-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T09:02:48Z","timestamp":1638435768000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-021-00932-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1186\/s12894-021-00932-2","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"8 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The Ethics Committee at Nippon Medical School Hospital approved this study (approval number: 30\u201303-1100). All study participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}